These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 15642077)
1. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Poirier B; Bidouard JP; Cadrouvele C; Marniquet X; Staels B; O'Connor SE; Janiak P; Herbert JM Diabetes Obes Metab; 2005 Jan; 7(1):65-72. PubMed ID: 15642077 [TBL] [Abstract][Full Text] [Related]
2. Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Després JP; Ross R; Boka G; Alméras N; Lemieux I; Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):416-23. PubMed ID: 19112166 [TBL] [Abstract][Full Text] [Related]
3. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. Després JP; Golay A; Sjöström L; N Engl J Med; 2005 Nov; 353(20):2121-34. PubMed ID: 16291982 [TBL] [Abstract][Full Text] [Related]
4. NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profile. Mastinu A; Pira M; Pani L; Pinna GA; Lazzari P Behav Brain Res; 2012 Oct; 234(2):192-204. PubMed ID: 22771813 [TBL] [Abstract][Full Text] [Related]
5. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice. Patel KN; Joharapurkar AA; Patel V; Kshirsagar SG; Bahekar R; Srivastava BK; Jain MR Can J Physiol Pharmacol; 2014 Dec; 92(12):975-83. PubMed ID: 25361428 [TBL] [Abstract][Full Text] [Related]
6. Adiponectin is required to mediate rimonabant-induced improvement of insulin sensitivity but not body weight loss in diet-induced obese mice. Migrenne S; Lacombe A; Lefèvre AL; Pruniaux MP; Guillot E; Galzin AM; Magnan C Am J Physiol Regul Integr Comp Physiol; 2009 Apr; 296(4):R929-35. PubMed ID: 19211723 [TBL] [Abstract][Full Text] [Related]
7. The central cannabinoid CB1 receptor is required for diet-induced obesity and rimonabant's antiobesity effects in mice. Pang Z; Wu NN; Zhao W; Chain DC; Schaffer E; Zhang X; Yamdagni P; Palejwala VA; Fan C; Favara SG; Dressler HM; Economides KD; Weinstock D; Cavallo JS; Naimi S; Galzin AM; Guillot E; Pruniaux MP; Tocci MJ; Polites HG Obesity (Silver Spring); 2011 Oct; 19(10):1923-34. PubMed ID: 21799481 [TBL] [Abstract][Full Text] [Related]
8. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. Pi-Sunyer FX; Aronne LJ; Heshmati HM; Devin J; Rosenstock J; JAMA; 2006 Feb; 295(7):761-75. PubMed ID: 16478899 [TBL] [Abstract][Full Text] [Related]
9. Effect of the cannabinoid receptor-1 antagonist rimonabant on inflammation in mice with diet-induced obesity. Wang Q; Perrard XD; Perrard JL; Mansoori A; Smith CW; Ballantyne CM; Wu H Obesity (Silver Spring); 2011 Mar; 19(3):505-13. PubMed ID: 20885384 [TBL] [Abstract][Full Text] [Related]
10. Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats. Janiak P; Poirier B; Bidouard JP; Cadrouvele C; Pierre F; Gouraud L; Barbosa I; Dedio J; Maffrand JP; Le Fur G; O'Connor S; Herbert JM Kidney Int; 2007 Dec; 72(11):1345-57. PubMed ID: 17882151 [TBL] [Abstract][Full Text] [Related]
11. Antiobesity and Lipid Lowering Effects of Orthosiphon stamineus in High-Fat Diet-Induced Obese Mice. Seyedan A; Alshawsh MA; Alshagga MA; Mohamed Z Planta Med; 2017 May; 83(8):684-692. PubMed ID: 27992939 [TBL] [Abstract][Full Text] [Related]
12. Addition of a low dose of rimonabant to orlistat therapy decreases weight gain and reduces adiposity in dietary obese rats. Zaitone SA; Essawy S Clin Exp Pharmacol Physiol; 2012 Jun; 39(6):551-9. PubMed ID: 22524969 [TBL] [Abstract][Full Text] [Related]
13. Involvement of adipokines in rimonabant-mediated insulin sensitivity in ob/ob mice. Mohapatra J; Sharma M; Singh S; Pandya G; Chatterjee A; Balaraman R; Patel PR; Jain MR J Pharm Pharmacol; 2009 Nov; 61(11):1493-8. PubMed ID: 19903374 [TBL] [Abstract][Full Text] [Related]
14. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity. Christopoulou FD; Kiortsis DN J Clin Pharm Ther; 2011 Feb; 36(1):10-8. PubMed ID: 21198716 [TBL] [Abstract][Full Text] [Related]
15. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. Van Gaal LF; Scheen AJ; Rissanen AM; Rössner S; Hanotin C; Ziegler O; Eur Heart J; 2008 Jul; 29(14):1761-71. PubMed ID: 18417461 [TBL] [Abstract][Full Text] [Related]
16. Anti-obesity effects of the combined administration of CB1 receptor antagonist rimonabant and melanin-concentrating hormone antagonist SNAP-94847 in diet-induced obese mice. Verty AN; Lockie SH; Stefanidis A; Oldfield BJ Int J Obes (Lond); 2013 Feb; 37(2):279-87. PubMed ID: 22473329 [TBL] [Abstract][Full Text] [Related]
17. Anti-obesity effects of Clausena excavata in high-fat diet-induced obese mice. Cho YR; Lee JA; Kim YY; Kang JS; Lee JH; Ahn EK Biomed Pharmacother; 2018 Mar; 99():253-260. PubMed ID: 29334669 [TBL] [Abstract][Full Text] [Related]
18. The cannabinoid CB1 receptor antagonist, rimonabant, protects against acute myocardial infarction. Lim SY; Davidson SM; Yellon DM; Smith CC Basic Res Cardiol; 2009 Nov; 104(6):781-92. PubMed ID: 19462153 [TBL] [Abstract][Full Text] [Related]
19. Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity. Tam J; Godlewski G; Earley BJ; Zhou L; Jourdan T; Szanda G; Cinar R; Kunos G Am J Physiol Endocrinol Metab; 2014 Feb; 306(4):E457-68. PubMed ID: 24381003 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Van Gaal L; Pi-Sunyer X; Després JP; McCarthy C; Scheen A Diabetes Care; 2008 Feb; 31 Suppl 2():S229-40. PubMed ID: 18227491 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]